Article (Scientific journals)
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
Vergote, I.; Bours, Vincent; Blaumeiser, B. et al.
2016In Facts, Views and Vision in Obgyn, 8 (3), p. 161-167
Peer Reviewed verified by ORBi
 

Files


Full Text
New Perspective Bours 2016.pdf
Publisher postprint (427.44 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
BRCA 1; BRCA 2; cancer; maintenance therapy; platinum-sensitive recurrent ovarian cancer
Abstract :
[en] Ovarian cancer (OC) is the seventh most common cancer in women. Although women diagnosed with OC are usually treated frontline with platinum-based chemotherapy, most of them relapse once treatment is halted. Therefore, maintenance therapies have been developed to secure the response and delay further chemotherapy. There are two established maintenance therapies for women affected by platinum-sensitive recurrent OC: bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, and olaparib, an inhibitor of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARPi). Loss-of-function mutations in genes in the homologous recombination pathway, especially BRCA1 and BRCA2, predict higher rates of platinum sensitivity, better overall survival (OS), and better response to PARPi in women with OC. Among patients with platinum-sensitive recurrent OC, a BRCA mutation is the first genetically defined predictive marker for targeted therapy, since these patients are most likely to benefit from treatment with a PARPi, such as olaparib. In patients with platinum-sensitive recurrent OC without a BRCA mutation, bevacizumab currently seems to be the best maintenance option. Women with OC are progressively more routinely screened for germline BRCA mutations, and the implication of somatic BRCA mutations is increasingly being recognized in OC. Therefore, the recommendations should be updated to reflect the importance of both types of mutations. Together, these data highlight the fact that treatment of recurrent OC can be optimized using genomic contributions to individualize therapy and to improve treatment response.
Disciplines :
Genetics & genetic processes
Author, co-author :
Vergote, I.
Bours, Vincent ;  Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
Blaumeiser, B.
Baurain, J.-F.
Language :
English
Title :
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
Publication date :
2016
Journal title :
Facts, Views and Vision in Obgyn
ISSN :
2032-0418
Publisher :
The Walking Egg Foundation, Wetteren, Belgium
Volume :
8
Issue :
3
Pages :
161-167
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 January 2017

Statistics


Number of views
36 (4 by ULiège)
Number of downloads
0 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi